CORDIS
EU research results

CORDIS

English EN

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation

Project information

Grant agreement ID: 223126

Status

Closed project

  • Start date

    1 April 2009

  • End date

    31 March 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 1 702 610,87

  • EU contribution

    € 1 000 000

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany

Objective

A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidemiological data, and by the ability to induce specific antibodies or potential protective responses in animals and later, in humans. Individual groups have developed assays within the context of the vaccine discovery efforts, with identification of measurable processes for parasite growth and virulence to test specific antigens. In-house assays are strain, stage and even process specific and the ability to compare results between different candidates is further limited by diverse methodologies and assay components such as parasites, cells and reagents. The absence of some level of harmonization of practices also makes interpreting the meaning and relevance of vaccine research outcomes complex. Lack of an enabling environment for comparability of research results generated in different labs could unfortunately lead to scepticism of the results that in turn generate uncertainty about the efficacy of the vaccines and rationale of the development pathway. To compare the relative merits of different candidate vaccines and approaches in a credible and informed manner, efforts must be made to create this enabling environment by supporting the development of a baseline level of standardization around key assays that can be utilized a) in the evaluation of malaria vaccines, and b) throughout the Development process. Consistent, reproducible and comparable intra- and inter-lab performance and increased accuracy and precision of assay data, will strengthen the quality of the data on vaccine performance and generate greater confidence in the vaccine potential of the candidate.

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV

Address

Vossstrasse 2 Geb 4040
69115 Heidelberg

Germany

Activity type

Research Organisations

EU Contribution

€ 294 512,11

Administrative Contact

Odile Leroy (Dr.)

Participants (13)

INSTITUT PASTEUR

France

EU Contribution

€ 100 000

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

Netherlands

EU Contribution

€ 55 224

STOCKHOLMS UNIVERSITET

Sweden

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 135 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 40 794

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 130 000

WORLD HEALTH ORGANIZATION

Switzerland

EU Contribution

€ 180 000

PATRICE MARTIN DUBOIS - IMMUNOVACC CONSULTING

Belgium

PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH

United States

FUNDACIO CENTRE DE RECERCA EN SALUT INTERNATIONAL DE BARCELONA

Spain

EU Contribution

€ 50 000

Public Health England an Executive Agency of the Dept of Health

United Kingdom

United States Department of Health and Human Services

United States

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 14 469,89

Project information

Grant agreement ID: 223126

Status

Closed project

  • Start date

    1 April 2009

  • End date

    31 March 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 1 702 610,87

  • EU contribution

    € 1 000 000

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany